Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock went on a downward path that fall over -6.92% on Wednesday, amounting to a one-week price increase of more than 5.87%.
Over the last 12 months, KPTI stock dropped by -22.20%. The one-year Karyopharm Therapeutics Inc stock forecast points to a potential upside of 84.0. The average equity rating for KPTI stock is currently 1.57, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $90.36 million, with 125.30 million shares outstanding and 115.36 million shares in the current float. Compared to the average trading volume of 936.11K shares, KPTI stock reached a trading volume of 408582 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Karyopharm Therapeutics Inc [KPTI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPTI shares is $4.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPTI stock is a recommendation set at 1.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Karyopharm Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 19, 2023. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $7 to $10. The new note on the price target was released on November 04, 2022, representing the official price target for Karyopharm Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while JP Morgan analysts kept a Neutral rating on KPTI stock. On November 19, 2021, analysts decreased their price target for KPTI shares from 27 to 10.
The Average True Range (ATR) for Karyopharm Therapeutics Inc is set at 0.06, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 0.61.
KPTI Stock Performance Analysis:
Karyopharm Therapeutics Inc [KPTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.87. With this latest performance, KPTI shares dropped by -6.80% in over the last four-week period, additionally sinking by -17.38% over the last 6 months – not to mention a drop of -22.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 47.78, with the RSI for the last a single of trading hit 48.18, and the three-weeks RSI is set at 47.21 for Karyopharm Therapeutics Inc [KPTI]. The present Moving Average for the last 50 days of trading for this stock 0.7869, while it was recorded at 0.7811 for the last single week of trading, and 0.9190 for the last 200 days.
Insight into Karyopharm Therapeutics Inc Fundamentals:
Karyopharm Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.93 and a Current Ratio set at 3.00.
Karyopharm Therapeutics Inc [KPTI] Institutonal Ownership Details
There are presently around $48.24%, or 51.43%% of KPTI stock, in the hands of institutional investors. The top three institutional holders of KPTI stocks are: VANGUARD GROUP INC with ownership of 7.65 million shares, which is approximately 6.6299%. PALO ALTO INVESTORS LP, holding 5.1 million shares of the stock with an approximate value of $$4.43 million in KPTI stocks shares; and PALO ALTO INVESTORS LP, currently with $$4.33 million in KPTI stock with ownership which is approximately 4.3196%.
